爱德士股票讨论区

The share price seems to largely reflect the EPS growth, indicating that investor sentiment towards the shares hasn't changed significantly. The company's consistent positive reception from the market suggests it may be worth watching for potential investment.

IDEXX Laboratories' high P/E ratio, inferior earnings outlook, and slower market growth could lead to a share price decline. This high P/E ratio may not be sustainable, posing a risk to shareholders and potential investors.

Long-term performance of IDEXX shows positive returns despite recent downturn. Market caution and strong momentum warrant closer scrutiny. Nonetheless, investors should note the existent 2 warning signs.

Comment:
Animal health companies ELAN, ZTS and IDXX are expecting a relatively uneventful Q2 following a turbulent Q1. For ZTS, the company is expected to see more normalized results for its companion business after distributor destocking in Q1. The company's new product cycle is forecasted to offset any macro challenges in Europe, and it remains the favorite AH name into the Librela US launch. Meanwhile, IDXX is expected to have an uneventful quarter with healt...